Expression of the CXCL12/CXCR4 chemokine axis predicts regional control in head and neck squamous cell carcinoma

Xavier León, Santiago Diez, Jacinto García, Joan Lop, Anna Sumarroca, Miquel Quer, Mercedes Camacho

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

© 2016, Springer-Verlag Berlin Heidelberg. Expression of the CXCL12/CXCR4 chemokine axis has been related with the appearance of metastatic recurrence survival, including regional and distant recurrence, in patients with head and neck squamous cell carcinoma (HNSCC). RT-PCR was used to determine mRNA expression levels of CXCL12 and CXCR4 in biopsy tumor samples in 111 patients with HNSCC. Five-year regional recurrence-free survival for patients with low CXCR4 expression (n = 39, 31.5 %) was 97.4 %, for patients with high CXCR4/high CXCL12 expression (n = 22, 19.8 %) it was 94.7 %, and for patients with high CXCR4/low CXCL12 expression (n = 50, 45.0 %) it was 63.3 %. We found significant differences in the regional recurrence-free survival according to CXCR4/CXCL12 expression values (P = 0.001). HNSCC patients with high CXCR4 and low CXCL12 expression values had a significantly higher risk of regional recurrence and could benefit from a more intense treatment of lymph node areas in the neck.
Original languageEnglish
Pages (from-to)4525-4533
JournalEuropean Archives of Oto-Rhino-Laryngology
Volume273
Issue number12
DOIs
Publication statusPublished - 1 Dec 2016

Keywords

  • Biomarker
  • CXCL12
  • CXCR4
  • Head and neck squamous cell carcinoma
  • Regional recurrence

Fingerprint

Dive into the research topics of 'Expression of the CXCL12/CXCR4 chemokine axis predicts regional control in head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this